Assay News and Research

RSS

AlloMap molecular expression test reduces need for invasive heart-muscle biopsies

Monitoring rejection in heart transplantation patients with a simple blood test co-developed by NewYork-Presbyterian Hospital/Columbia University Medical Center physician-scientist Dr. Mario Deng in 2005 can safely reduce their need for invasive heart-muscle biopsies, a new study has found.

24 Apr 2010

University of Granada scientists create artificial human skin with dermis made of fibrin-agarose biomaterial

23 Apr 2010

Gen-Probe's PROGENSA PCA3 assay helps determine necessity of initial biopsy in prostate cancer suspect men

Gen-Probe's PROGENSA® PCA3 assay can help predict the outcome of initial prostate biopsies in men suspected of having prostate cancer, according to a study of the molecular urine test presented in a scientific poster last week at the 25th annual European Association of Urology (EAU) Congress in Barcelona, Spain.

22 Apr 2010

Biomagnetics Diagnostics receives commitment for clinical validation testing in India for malaria, TB diagnosis

Biomagnetics Diagnostics Corp., a developer of revolutionary diagnostic systems and technology for HIV, hepatitis, tuberculosis and malaria detection, today announced it has received important commitments from two leading research laboratories in India for clinical validation testing for malaria and tuberculosis (TB) detection and diagnosis.

21 Apr 2010

Clarient Insight Dx Pulmotax assay helps predict response to chemotherapy in lung cancer patients

Clarient, Inc., a premier technology and services resource for pathologists, oncologists and the pharmaceutical industry, today announced that data from a new study suggest that the Clarient Insight® Dx Pulmotax™ assay may effectively predict which lung cancer patients will respond favorably to chemotherapy. The study, titled "TLE3 expression is predictive of response to chemotherapy in NSCLC," included 368 samples from carcinoma patients.

21 Apr 2010

Immunomedics' blood assay for PAM4-protein can detect pancreatic cancer and predict early relapse

Immunomedics, Inc., a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today reported that a new blood test using the Company's proprietary humanized antibody, clivatuzumab or PAM4, predicted a partial response in an initial set of patients treated with a combination of the antibody labeled with yttrium-90 (Y-90) and gemcitabine. Results were presented at the 101st Annual Meeting of the American Association for Cancer Research.

21 Apr 2010

ARIAD presents AP26113 investigational ALK inhibitor preclinical study data at AACR annual meeting

ARIAD Pharmaceuticals, Inc. today announced results of preclinical studies on its investigational anaplastic lymphoma kinase (ALK) inhibitor - AP26113 - showing potent inhibition of the target protein and of mutant forms that are resistant to the first-generation ALK inhibitor, which currently is in clinical trials in patients with cancer. ARIAD scientists presented these data today at the annual meeting of the American Association for Cancer Research (AACR) in Washington, D.C.

21 Apr 2010

Elan's first-quarter total revenue up by 27% to $310.5M

Elan Corporation, plc, today reported its first quarter 2010 financial results.

21 Apr 2010

ForteBio introduces new Octet QK(e) instrumentation system

ForteBio®, Inc., a leading supplier of label-free technology that accelerates the development of biotherapeutic and pharmaceutical products, today announced the launch of its new Octet QK(e) instrumentation system. The new system, the next generation of the company's initial eight-channel Octet QK instrument, provides significantly increased sensitivity, enabling analysis of small proteins and peptides. Additionally, the Octet QK(e) system enables biosensors to be re-racked, for increased workflow flexibility and cost savings.

20 Apr 2010

AMRI extends and expands research collaboration with CHDI Foundation

AMRI announced today the five year extension and expansion of its ongoing research collaboration with CHDI Foundation, Inc. (CHDI), focused on the discovery of new therapeutic agents for the treatment of Huntington's disease (HD).

20 Apr 2010

TYSABRI drives Biogen Idec's first-quarter revenues of $1.1 billion

Biogen Idec Inc., a global biotechnology leader in the discovery, development, manufacturing, and commercialization of innovative therapies, today announced its first quarter 2010 results.

20 Apr 2010

Affymetrix introduces new service for obtaining allele-specific copy number data from FFPE samples

Affymetrix, Inc. today announced the launch of the Affymetrix® MIP Copy Number Service, designed for cancer researchers using challenging FFPE samples. With the MIP Copy Number Service, scientists can now obtain high-quality allele-specific copy number data from FFPE samples. The service is available for research use only exclusively through the Affymetrix® Research Services Laboratory (ARSL).

20 Apr 2010

Artificial human skin with dermis made from fibrin-agarose biomaterial

Scientists from the University of Granada, Spain, have generated artificial human skin by tissular engineering basing on agarose-fibrin biomaterial. The artificial skin was grafted onto mice, and optimal development, maturation and functionality results were obtained. This pioneering finding will allow the clinical use of human skin and its use in many laboratory tests on biological tissues -which, additionally, would avoid the use of laboratory animals.

20 Apr 2010

Gamma-prime fibrinogen test can help better predict people at risk for heart attack

A simple blood test can identify people who are at risk for a heart attack, including thousands who don't have high cholesterol, according to researchers at Oregon Health & Science University.

20 Apr 2010

S1P5 may serve as future strategy in biotherapy for esophageal cancer: Study

Esophageal cancer is one of the most common malignancies worldwide. Its mortality is very high due to relatively late diagnosis and inefficient treatment. The ability to reverse the outcome of esophageal cancer is limited due to a poor understanding of its biology. Progression of esophageal cancer may be associated with sphingosine 1-phosphate and its receptors S1P1-5, which play an important role in other cancers.

20 Apr 2010

NanoString Technologies launches new miRNA assay kits

NanoString Technologies, Inc., a privately held life sciences company marketing a complete solution for detecting and counting large sets of target molecules in biological samples, today announced a unique new product for miRNA analysis that includes a multiplexed assay for profiling the human miRNA transcriptome in a single tube. The company introduced the new assay kit, which expands the applications for its nCounter® Analysis System, at the American Association for Cancer Research annual meeting.

From NanoString Technologies 20 Apr 2010

Positive data from NewLink Genetics Phase1/2 study of HyperAcute-Lung cancer immunotherapy

NewLink Genetics Corporation announced today data from a Phase 1/2 study showing that patients with progressive advanced non-small cell lung cancer treated with its HyperAcute®-Lung cancer immunotherapy experienced favorable median survival. The data were presented at the 101st American Association for Cancer Research (AACR) Annual Meeting.

20 Apr 2010

ITI granted AOAC approval for additional Salmonella matrices

Idaho Technology, Inc. (ITI) has received AOAC Performance Tested Method approval for two additional Salmonella matrices—stainless steel environmental samples and dry pet food. These matrices join the list of already approved matrices in the Salmonella LT Food Security System including chocolate, cooked ham, fresh raw chicken, lettuce, raw ground beef, and liquid whole eggs. This assay uses real-time PCR technology to identify the presence of Salmonella in less than one hour after a pre-enrichment period.

20 Apr 2010

SPI-Bio to distribute and sell Aterovax's sPLA2 activity test in Europe

Aterovax SA, a company developing innovative products for atherosclerosis, today announced the signing of a 3 year, exclusive agreement with SPI-Bio, a specialist distributor of products and services in drug development, to distribute and sell Aterovax's sPLA2 activity test in Europe to academic and research laboratories for research use.

19 Apr 2010

TGen, Asuragen sign microRNA technology agreement for pancreatic cancer research

The Translational Genomics Research Institute and Asuragen Inc. today announced a research agreement that could lead to ways of detecting cancer before it spreads.

17 Apr 2010

Assay News and Research

AlloMap molecular expression test reduces need for invasive heart-muscle biopsies

University of Granada scientists create artificial human skin with dermis made of fibrin-agarose biomaterial

Gen-Probe's PROGENSA PCA3 assay helps determine necessity of initial biopsy in prostate cancer suspect men

Biomagnetics Diagnostics receives commitment for clinical validation testing in India for malaria, TB diagnosis

Clarient Insight Dx Pulmotax assay helps predict response to chemotherapy in lung cancer patients

Immunomedics' blood assay for PAM4-protein can detect pancreatic cancer and predict early relapse

ARIAD presents AP26113 investigational ALK inhibitor preclinical study data at AACR annual meeting

Elan's first-quarter total revenue up by 27% to $310.5M

ForteBio introduces new Octet QK(e) instrumentation system

AMRI extends and expands research collaboration with CHDI Foundation

TYSABRI drives Biogen Idec's first-quarter revenues of $1.1 billion

Affymetrix introduces new service for obtaining allele-specific copy number data from FFPE samples

Artificial human skin with dermis made from fibrin-agarose biomaterial

Gamma-prime fibrinogen test can help better predict people at risk for heart attack

S1P5 may serve as future strategy in biotherapy for esophageal cancer: Study

NanoString Technologies launches new miRNA assay kits

Positive data from NewLink Genetics Phase1/2 study of HyperAcute-Lung cancer immunotherapy

ITI granted AOAC approval for additional Salmonella matrices

SPI-Bio to distribute and sell Aterovax's sPLA2 activity test in Europe

TGen, Asuragen sign microRNA technology agreement for pancreatic cancer research

eBook: Using iPSCs models for human disease research and drug discovery eBook

Decoding Cannabis: Differentiating Hemp and Marijuana

Deciphering the Microbiome with The Microsetta Initiative

Leveraging the power of automation to boost research

Latest News